Eledon Pharmaceuticals, Inc. is rated a Strong Buy following positive phase 2 BESTOW results for tegoprubart. Read more on ...
Clinically available KRAS inhibitors mainly target G12C, which is rare in PDAC and often acquires resistance. Oncogenic KRAS ...
Everyday Health on MSN
C3G/IC-MPGN progression: Can new C3 inhibitors stop the path to dialysis?
For years, patients with C3G and IC-MPGN had few options to stop the progression toward kidney failure. Now a new class of ...
Clinically available KRAS inhibitors mainly target G12C, which is rare in PDAC and often acquires resistance. Oncogenic KRAS inactivates RB1 via CDK4/6, while RB1 mutation is rare. Thus, CDK4/6 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results